Fisetin for lipocalin 1

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
UK Healthcare at Turfland, Lexington, KY
lipocalin 1+3 More
Fisetin - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

Arthroscopic meniscal procedures are the most commonly performed orthopaedic procedure in the U.S. affecting 15% of Americans ages 10-65 years. Meniscus injury is also known to increase the risk of posttraumatic osteoarthritis (PTOA). The current randomized clinical trial will test a novel intervention after meniscal repair that combines an oral senolytic fisetin and real-time biofeedback program to restore joint loading and subsequent return to activity.

Eligible Conditions

  • Meniscus Disorder
  • lipocalin 1
  • Meniscus Lesion
  • Meniscus; Derangement

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline, 1 year

Baseline, 1 year
Change in International Knee Documentation Committee (IKDC) Score between baseline and 1 year
Change in MRI T1rho between baseline and 1 year

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Fisetin
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

38 Total Participants · 2 Treatment Groups

Primary Treatment: Fisetin · Has Placebo Group · Phase 2 & 3

Fisetin
Drug
Experimental Group · 1 Intervention: Fisetin · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral capsule · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 1 year
Closest Location: UK Healthcare at Turfland · Lexington, KY
Photo of Lexington 1Photo of Lexington 2Photo of Lexington 3
2019First Recorded Clinical Trial
0 TrialsResearching lipocalin 1
3 CompletedClinical Trials

Who is running the clinical trial?

Austin V StoneLead Sponsor
4 Previous Clinical Trials
84 Total Patients Enrolled
Austin Stone, MD, PhDPrincipal InvestigatorUniversity of Kentucky
2 Previous Clinical Trials
6 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between the ages of 18 and 45.
You have a medial, lateral or combined meniscus tear that has been treated with surgical repair.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.